All In Biotech

Drug Trial Radar · NCT06132217

A Study of Simmitinib Plus SG001 in Advanced Solid Tumors

A Phase I/II Study To Evaluate The Safety, Tolerability, Pharmacokinetic Profile And Preliminary Efficacy Of Simmitinib Plus SG001 in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

168

Planned (sponsor's estimate)

Start

Jan 30, 2024

Primary completion

Jan 30, 2027

Study completion Jan 30, 2027

Sponsor

Sponsor type
Industry
First posted
Nov 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label Phase I/II trial of simmitinib plus SG001 in patients with advanced solid tumors. Phase I will determine and confirm the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) for simmitinib in combination with SG001 in patients with advanced solid tumors. Phase 2 (Expansion) will evaluate the safety and efficacy of the combination in 3 cohorts at the RP2D from Phase I.

Conditions

  • Advanced Solid Tumor

Interventions

  • SimmitinibDrug

    Patients will oral administration according to study protocol until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria.

  • SG001Drug

    Patients will receive intravenous infusion of SG001 according to study protocol until disease progression, unacceptable toxicity, meeting the suspension or termination criteria, or up to 24 months in patients without disease progression.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation Phase: Dose Limited Toxicity (DLT)Time frame: From Cycle 1 Day 1 to Cycle 1 Day 28(each cycle is 28 days)
  2. Dose Escalation Phase: Maximum Tolerated Dose (MTD)Time frame: From Cycle 1 Day 1 to Cycle 1 Day 28(each cycle is 28 days)
  3. Dose Escalation Phase: Recommended Phase 2 Dose (RP2D)Time frame: From Cycle 1 Day 1 to Cycle 1 Day 28(each cycle is 28 days)
  4. Dose Escalation Phase-Incidence rate of Adverse Event (AE).Time frame: From first dose to 30 days post the last dose, with approximately 3 years
  5. Dose Expansion Phase - Objective Response Rate (ORR) evaluated by Independent Review Committee (IRC) or investigators in advanced solid tumor based on RECIST 1.1.Time frame: Up to approximately 3 years.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.